Louise Frederika Kooij Sells 150,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

Key Points

• Louise Frederika Kooij, the Chief Accounting Officer of NewAmsterdam Pharma, sold 150,000 shares at an average price of $25.83, significantly reducing her ownership in the company by approximately 90.91%.
• NewAmsterdam Pharma's stock recently rose by 1.1% to $26.90, with strong trading volume exceeding its average volume.
• The company reported earnings per share of ($0.15), outperforming expectations, and analysts anticipate a target price average of $41.55 for the stock.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the completion of the sale, the chief accounting officer owned 15,000 shares in the company, valued at $387,450. This represents a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Wednesday, September 3rd, Louise Frederika Kooij sold 18,073 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.09, for a total transaction of $453,451.57.
• On Monday, August 25th, Louise Frederika Kooij sold 8,269 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $24.86, for a total transaction of $205,567.34.

NewAmsterdam Pharma Stock Down 0.3%

Shares of NewAmsterdam Pharma stock traded down $0.07 on Monday, hitting $24.12. The company's stock had a trading volume of 1,037,570 shares, compared to its average volume of 968,191. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $27.35. The firm has a fifty day moving average price of $23.76 and a 200-day moving average price of $20.84. The company has a market capitalization of $2.72 billion, a P/E ratio of -14.89 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. The company had revenue of $19.15 million for the quarter, compared to analyst estimates of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. As a group, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NAMS. Wells Fargo & Company began coverage on shares of NewAmsterdam Pharma in a report on Monday, August 25th. They issued an "overweight" rating and a $45.00 target price on the stock. The Goldman Sachs Group began coverage on shares of NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price on the stock. Citigroup began coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price on the stock. Royal Bank Of Canada upped their target price on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Finally, Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $41.55.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Quarry LP purchased a new position in shares of NewAmsterdam Pharma during the 1st quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. increased its position in NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after purchasing an additional 596 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in NewAmsterdam Pharma by 130.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after purchasing an additional 3,390 shares in the last quarter. Finally, Avanza Fonder AB acquired a new stake in NewAmsterdam Pharma during the 1st quarter worth approximately $127,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.